Bexson Biomedical is developing a unique formulation of ketamine for chronic and acute pain disorders. The opioid crisis is a Public Health Emergency in the United States. There is a desperate need for safe and potent treatments that can offer a real alternative to opioid-based pain management to millions of people in pain.
Bexson’s lead project is a novel ketamine delivery system that includes a proprietary formulation of ketamine delivered by a minimally invasive, wearable, subcutaneous infusion pump.
Pain management has not seen meaningful innovation in a long time, even despite the severity national opioid crises. Bexson's new pain treatments will bridge this gap for both rare pain diseases and large market pain indications.
In February 2019 Bexson was granted Orphan Status for ketamine in the treatment of Complex Regional Pain Syndrome, our lead indication. In parallel, we are targeting post operative pain management and other large market indications.
Bexson Biomedical is developing a non-opioid therapy for chronic and acute pain management based upon a unique formulation of ketamine for subcutaneous delivery. Ketamine is an anesthetic with powerful pain relieving properties. Bexson is is solving the pharmacokinetic issues presented by this useful molecule to allow exquisite control over dosing and achieve pain relief in multiple pain disorders. A safe and effective low-dose ketamine strategy for use in the home environment will be a game changer for difficult to treat pain conditions. It would reimagine pain management.
Bexson’s lead development project is a new subcutaneous delivery system that includes formulation innovations tuned to a minimally invasive, wearable, subcutaneous infusion pump with anti-diversion properties. The safety and dynamic dosing control offered by our product will be a game changer in acute and chronic pain management. The United States and the world are desperately in need of powerful non-addictive pain treatments and Bexson Biomedical is meeting that need.